1. A 68-year-old man with primary open-angle glaucoma (IOP 28 mmHg bilaterally), moderate COPD (FEV1 58% predicted, on tiotropium), and hypertension is started on timolol 0.5% eye drops twice daily. Two weeks later he presents to his pulmonologist with worsening dyspnea and a 15% reduction in FEV1. Which of the following most accurately explains the mechanism of his pulmonary deterioration and identifies the preferred alternative glaucoma agent?

• A) Timolol is a non-selective beta-adrenergic blocker (blocking both beta-1 and beta-2 receptors) -- even though administered topically as an eye drop, timolol is absorbed systemically via the nasolacrimal duct drainage into the nasal mucosa and GI tract, bypassing first-pass hepatic metabolism; systemically absorbed timolol blocks beta-2 receptors in bronchial smooth muscle, removing the sympathetic bronchodilatory counterbalance to resting vagal M3-mediated bronchomotor tone and precipitating bronchoconstriction; in COPD patients with pre-existing bronchial hyperresponsiveness, even small amounts of systemic timolol can produce clinically significant bronchoconstriction; the FEV1 reduction represents real beta-2-mediated bronchospasm, not spirometric artifact; preferred alternative: brimonidine (selective alpha-2 agonist -- reduces aqueous humor production and increases uveoscleral outflow, no beta-adrenergic activity, no pulmonary effect) or a topical carbonic anhydrase inhibitor (dorzolamide, brinzolamide -- reduces aqueous humor production by inhibiting ciliary body CA-II and CA-XII, no adrenergic mechanism, no pulmonary effect); prostaglandin analogs (latanoprost, travoprost) are also safe in COPD.
• B) Timolol is a beta-1 selective blocker that acts only on cardiac beta-1 receptors -- the pulmonary deterioration is unrelated to timolol and represents natural COPD progression; beta-1 selective blockers do not affect bronchial beta-2 receptors at therapeutic doses; the appropriate management is to increase the dose of tiotropium rather than change the glaucoma therapy; the cardiologist should be consulted regarding the patient's timolol use for hypertension co-management.
• C) Timolol reduces intraocular pressure by blocking beta-2 receptors on the ciliary body epithelium -- the same beta-2 receptors are also expressed in bronchial smooth muscle; however, topical timolol does not produce systemic absorption because the corneal epithelium acts as an effective barrier, preventing drug penetration beyond the anterior chamber; the FEV1 reduction reflects reactive airways disease triggered by the benzalkonium chloride preservative in timolol eye drops, not beta-2 blockade; preservative-free timolol should be tried before changing the medication class.
• D) Timolol is a non-selective beta-blocker (beta-1 and beta-2) administered topically -- it reduces IOP by blocking beta-2 receptors on the ciliary body epithelium (which use beta-2-cAMP signaling to drive aqueous humor production); systemic absorption via nasolacrimal drainage produces beta-2 blockade in the lungs, precipitating bronchoconstriction in this COPD patient; pressing the inner canthus (nasolacrimal occlusion) for 1-2 minutes after instillation reduces systemic absorption by approximately 70% but does not eliminate the risk in severe COPD; the preferred agents that achieve IOP reduction without any beta-adrenergic mechanism include: prostaglandin analogs (latanoprost, bimatoprost -- increase uveoscleral outflow via FP receptor activation), brimonidine (alpha-2 agonist reducing aqueous production and increasing uveoscleral outflow), and topical carbonic anhydrase inhibitors (dorzolamide, brinzolamide).

2. A 58-year-old woman with hypertension and benign prostatic hyperplasia (BPH) in her husband is being discussed at a case conference. The patient herself has stress urinary incontinence and overactive bladder. The pharmacology resident is asked to compare the receptor mechanisms of alpha-1 blockers used for BPH versus muscarinic antagonists used for overactive bladder, and explain why an alpha-1 blocker would be inappropriate for her overactive bladder while a muscarinic antagonist would be inappropriate for her husband's BPH symptoms. Which of the following most accurately constructs this pharmacological distinction?

• A) Alpha-1 blockers (tamsulosin, doxazosin) reduce BPH symptoms by blocking alpha-1A receptors on prostatic smooth muscle and the bladder neck, reducing urethral resistance and improving voiding; they would not help overactive bladder because the problem in OAB is detrusor overactivity (inappropriate detrusor contractions during filling) mediated by M3 muscarinic receptors, not alpha-1-mediated outflow obstruction; giving an alpha-1 blocker to a woman with OAB would reduce the already-normal urethral resistance without addressing detrusor overactivity, potentially worsening stress incontinence by reducing sphincter tone; muscarinic antagonists (oxybutynin, tolterodine, solifenacin) reduce OAB symptoms by blocking M3 receptors on the detrusor, suppressing uninhibited contractions during filling; in BPH, the problem is mechanical outflow obstruction from enlarged prostate plus dynamic alpha-1-mediated smooth muscle tone -- muscarinic antagonists would reduce detrusor contraction strength, potentially causing urinary retention in a man with already-impaired voiding due to prostatic obstruction; in practice, muscarinic antagonists can be used cautiously in BPH with OAB symptoms after adequate alpha-blocker therapy if post-void residual is low.
• B) Alpha-1 blockers are appropriate for both BPH and overactive bladder because both conditions involve excess alpha-1 adrenergic tone -- BPH causes alpha-1A-mediated prostatic smooth muscle constriction of the urethra, and OAB causes alpha-1D-mediated detrusor smooth muscle overactivity; tamsulosin (alpha-1A selective) would address the BPH component while doxazosin (non-selective alpha-1) would address the OAB component by also blocking alpha-1D receptors; muscarinic antagonists are inappropriate for both conditions because blocking M3 receptors on detrusor prevents the coordinated detrusor contraction required for normal voiding in both men and women.
• C) The pharmacological distinction is based on the two-phase model of micturition: filling phase (sympathetic dominant -- alpha-1 mediates internal sphincter closure, beta-3 mediates detrusor relaxation) and voiding phase (parasympathetic dominant -- M3 mediates detrusor contraction, alpha-1 relaxes to allow opening); BPH symptoms reflect filling and voiding phase dysfunction from outflow obstruction -- alpha-1 blockers address dynamic outflow resistance; OAB reflects filling phase dysfunction from inappropriate detrusor contractions -- M3 antagonists suppress these while beta-3 agonists (mirabegron) promote filling-phase detrusor relaxation; combining alpha-1 blockers with M3 antagonists in BPH with OAB symptoms addresses both dynamic obstruction and detrusor overactivity but requires monitoring post-void residual.
• D) Muscarinic antagonists are the first-line treatment for BPH because the prostate smooth muscle contains predominantly M3 muscarinic receptors rather than alpha-1 adrenergic receptors -- the alpha-1 blocker story in BPH is a historical misconception; modern prostate biopsies show M3 receptor dominance in periurethral smooth muscle; the success of tamsulosin in BPH is actually due to its significant muscarinic antagonist activity at M3 receptors in the prostate rather than its alpha-1A blocking properties; alpha-1 blockers such as doxazosin lower blood pressure as their primary mechanism and improve BPH symptoms only as a secondary antihypertensive vasodilatory effect.

3. A 44-year-old woman presents to the endocrinology clinic with a 5.8 cm right adrenal mass. Plasma metanephrines are markedly elevated (normetanephrine 8.2 nmol/L, metanephrine 3.4 nmol/L). Blood pressure is 188/118 mmHg with episodic hypertensive surges to 240/150 mmHg accompanied by headache, diaphoresis, and palpitations. She is scheduled for laparoscopic adrenalectomy in three weeks. The endocrinologist begins preoperative pharmacological preparation. Which of the following most accurately explains the required preoperative receptor-targeted preparation and the sequence in which drug classes must be initiated?

• A) Preoperative pheochromocytoma preparation requires alpha-blockade initiated FIRST (at least 7-14 days before surgery) followed by beta-blockade ONLY after adequate alpha-blockade is established -- this sequence is mandatory because initiating beta-blockade first in a catecholamine-excess state blocks beta-2-mediated vasodilation in skeletal muscle vasculature, leaving alpha-1-mediated vasoconstriction from tumor-secreted catecholamines unopposed, precipitating severe hypertensive crisis; phenoxybenzamine (irreversible alpha-1 and alpha-2 blocker) is the traditional first-line alpha-blocker -- its irreversible binding provides sustained alpha-blockade that cannot be overcome by catecholamine surges during tumor manipulation; alternatively, doxazosin or prazosin (reversible selective alpha-1 blockers) can be used; after 7-14 days of alpha-blockade allowing vascular bed expansion (patients are chronically volume-depleted from catecholamine-induced venoconstriction), beta-blockade (propranolol or atenolol) is added to control reflex tachycardia; high-sodium diet and fluid loading during alpha-blockade phase corrects volume contraction; goals before surgery: BP consistently below 130/80 mmHg, heart rate 60-70 bpm, no ST-segment changes, nasal congestion (a sign of adequate alpha-blockade producing vasodilation in the nasal mucosa).
• B) The correct preoperative preparation is: begin beta-blockade first (metoprolol or atenolol) to control the episodic tachycardia, then add alpha-blockade (phenoxybenzamine) after heart rate is controlled; beginning with alpha-blockade first is dangerous because the vasodilation it produces will cause baroreceptor-mediated reflex tachycardia that the tumor's catecholamine output will amplify into hypertensive crisis; the beta-first approach controls heart rate before vasodilation is induced, preventing this dangerous sequence; volume expansion with IV saline is initiated simultaneously with beta-blockade to prevent orthostatic hypotension.
• C) Preoperative preparation for pheochromocytoma is optional since the surgical team can control intraoperative hypertensive surges with IV phentolamine and nitroprusside -- outpatient pharmacological preparation adds risk (orthostatic hypotension, falls) without improving surgical outcomes; the three weeks until surgery should be used for cardiac evaluation and imaging rather than alpha-blockade; beta-blockers should be started perioperatively to control heart rate during anesthesia induction.
• D) The correct preoperative sequence is: begin calcium channel blocker first (amlodipine or nicardipine) to control BP through a mechanism entirely independent of adrenergic receptors, avoiding any interaction with the tumor's catecholamine output; after BP is controlled with CCB for one week, add doxazosin (selective alpha-1 blocker) for additional control; beta-blockade is not required preoperatively in pheochromocytoma patients who are receiving both CCB and alpha-blockade because adequate calcium channel blockade at the SA node provides heart rate control without the dangerous alpha-blockade-before-beta-blockade sequencing requirement.

4. A 77-year-old man with benign prostatic hyperplasia, mild dementia, and narrow-angle glaucoma is prescribed oxybutynin 5 mg three times daily for urinary urgency. One week later he is brought to the emergency department by his family with acute confusion, visual hallucinations, and urinary retention. His ophthalmologist notes bilateral fixed dilated pupils (6 mm) and cloudy corneas. Which of the following most accurately explains the complete receptor-based mechanism of each of his three new problems?

• A) Oxybutynin is a non-selective muscarinic antagonist with moderate CNS penetration (tertiary amine structure) -- urinary retention results from M3 blockade at the detrusor muscle (preventing coordinated detrusor contraction needed for voiding) compounded by M3 blockade at the bladder neck reducing the normal voiding-phase reduction in outlet resistance; in his already-compromised BPH prostate, this detrusor paralysis tips him into acute urinary retention; acute confusional state and visual hallucinations result from CNS muscarinic M1 and M4 blockade in a vulnerable elderly patient with pre-existing cognitive impairment -- muscarinic blockade in the CNS impairs cholinergic neurotransmission in cortical circuits underlying attention, memory encoding, and reality testing, producing anticholinergic delirium; acute angle-closure glaucoma results from M3 blockade at the iris sphincter pupillae (preventing pupillary constriction) causing maximal iris dilator alpha-1 tone to dominate, producing mydriasis -- the dilated iris bunches up at the iridocorneal angle, physically obstructing aqueous humor outflow through the trabecular meshwork and Schlemm's canal, causing acute IOP elevation; the cloudy cornea reflects corneal edema from elevated IOP impairing aqueous outflow across the corneal endothelium.
• B) Oxybutynin produces acute urinary retention through alpha-1 agonism at the bladder neck (a poorly understood secondary mechanism independent of its primary muscarinic antagonism) -- this alpha-1 effect is unique to oxybutynin and not shared by other muscarinic antagonists; the confusion is from oxybutynin's opioid receptor partial agonism in the CNS (a pharmacological property of all tertiary amine muscarinic antagonists); the acute glaucoma results from direct oxybutynin-induced aqueous humor overproduction through M2 receptor blockade at the ciliary body (M2 normally inhibits aqueous production, so M2 blockade increases it).
• C) The triad of acute confusion, urinary retention, and acute angle-closure glaucoma from oxybutynin represents the full anticholinergic toxidrome in a patient with multiple vulnerabilities: (1) detrusor paralysis from M3 blockade -> urinary retention compounded by BPH outflow obstruction; (2) central M1/M4 blockade -> anticholinergic delirium (confusion, hallucinations, agitation) in a patient with pre-existing cognitive vulnerability -- elderly patients with dementia have reduced cholinergic reserve (loss of basal forebrain cholinergic neurons), making them exquisitely sensitive to anticholinergic delirium; (3) M3 blockade of the iris sphincter pupillae -> mydriasis -> angle closure in a patient with anatomically narrow anterior chamber angles (pre-existing narrow-angle anatomy is required -- oxybutynin does not cause angle-closure in patients with normal anterior chamber depth); treatment: physostigmine IV (tertiary AChE inhibitor penetrating CNS) for life-threatening anticholinergic CNS toxicity; immediate ophthalmology for acute angle-closure (pilocarpine eye drops to constrict pupil and open angle, IV acetazolamide, topical beta-blocker after IOP lowered); replace oxybutynin with mirabegron (beta-3 agonist for OAB -- no muscarinic mechanism, no CNS anticholinergic effects, no IOP effects).
• D) Oxybutynin's adverse effects in this patient are entirely predictable from its non-selective muscarinic antagonism: M3 blockade at detrusor (urinary retention) + M1/M4 blockade in CNS (anticholinergic delirium, particularly severe in dementia) + M3 blockade at iris sphincter (mydriasis triggering angle-closure in anatomically predisposed narrow anterior chamber) -- this case illustrates the STOPP criteria and Beer's List contraindications to anticholinergic drugs in elderly patients; oxybutynin is on the Beer's List as a potentially inappropriate medication in adults over 65 due to CNS anticholinergic effects; preferred alternatives for OAB in elderly or cognitively impaired patients: mirabegron (beta-3 agonist, no anticholinergic effects) or trospium (quaternary ammonium muscarinic antagonist, minimal CNS penetration due to poor lipid solubility, less delirium risk); narrow-angle glaucoma is an absolute contraindication to all muscarinic antagonists.